Severe cases of COVID-19 require intensive care and mechanical ventilation with an average duration of 12 days. Moreover, liberating patients from mechanical ventilation takes time and ties up staff resources. To help speed up the time to the recovery of patients in intensive care, STIMIT developed a breathing stimulation device to enable faster recovery through diaphragm stimulation.
The solution is backed by a technology that can non-invasively activate the body's own breathing function. The goal of the therapy is to maintain the breathing muscle function during ventilation, minimize life-threatening damage to the lungs from mechanical ventilation, and shorten the duration of ventilation for intensive-care patients.
To speed up development to support patients suffering from the effects of the COVID-19, STIMIT has received CHF 150'000 as part of the ’Venture Kick Life Science‘, a special track for biotech and medtech startups launched early this year. STIMIT becomes the first company benefiting from this pilot project support.
"Currently we focus on bringing our breathing stimulation device to the market and we must not lose time", says Ronja Bruhn, founder of STIMIT. "Venture Kick’s additional support will accelerate STIMIT in bringing this novel therapy and device to market. Our goal is to improve outcomes in ventilated patients and treat more patients in less time."
(Press release/ran)
Photo L-R: Peter Frei, Board Member; Olivier Mülller, co-founder; Ronja Brühn, CEO and co-founder; Hans Pargger, Customer Perspective.
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
Please login or sign up to comment.
Commenting guidelines